---
title: "H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289088253.md"
description: "H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on LB Pharmaceuticals (LBRX) with a $45 price target. The broader analyst consensus for LBRX is Strong Buy, with an average price target of $46.83."
datetime: "2026-06-08T17:35:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289088253.md)
  - [en](https://longbridge.com/en/news/289088253.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289088253.md)
---

# H.C. Wainwright Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on LB Pharmaceuticals, Inc., with a price target of $45.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Aclaris Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 18.4% and a 50.10% success rate on recommended stocks.

Currently, the analyst consensus on LB Pharmaceuticals, Inc. is a Strong Buy with an average price target of $46.83.

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)
- [EBS.US](https://longbridge.com/en/quote/EBS.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)

## Related News & Research

- [LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained](https://longbridge.com/en/news/293644868.md)
- [LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per share](https://longbridge.com/en/news/294206557.md)
- [Meet the Gen Z AI whiz at the center of a hedge fund meltdown](https://longbridge.com/en/news/294425537.md)
- [Pendle: AI Yield Tools connect Claude and ChatGPT to autonomous yield execution - 27 Jul 2026](https://longbridge.com/en/news/293868624.md)
- [Northland Securities Keeps Their Buy Rating on Rezolve AI (RZLV)](https://longbridge.com/en/news/294092952.md)